Skip to main content
SpringerLink
Log in

Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Although the CB1 receptor antagonist/inverse agonist rimonabant acutely suppresses food intake in rodents, the behavioural specificity of this effect remains unclear.

Objectives

To profile the behavioural effects of rimonabant in a free-feeding context.

Materials and methods

Videoanalysis was employed to characterise the effects of acute rimonabant (1.5 and 3.0 mg/kg, IP) on the behaviour of non-deprived male rats exposed to palatable mash. Data were also collected on post-treatment weight gain, and, as prolonged appetite suppression has been found after single dosing with compounds of this series, rats were reassessed (drug-free) for food intake 7 days after initial testing.

Results

Both doses of rimonabant not only decreased mash consumption (44–55%) but also reduced 24-h weight gain. Although videoanalysis confirmed the inhibitory effects of rimonabant on feeding behaviour, it also revealed concurrent reductions in locomotion, rearing and sniffing as well as substantial (up to tenfold) and dose-dependent increases in grooming and scratching. Timecourse analyses further revealed that rimonabant dose-dependently induced frequent episodes of atypical scratching that waned over the test but which were succeeded by prolonged and behaviourally disruptive grooming. Finally, as groups did not differ in mash consumption on retest, any prolonged anorectic effect of acute rimonabant dissipates within 7 days of treatment.

Conclusions

The anorectic response to rimonabant in male rats would appear to be due largely to response competition. This parsimonious conclusion is supported by the less profound (although still significant) increases in scratching and grooming observed in rats treated with a sub-anorectic dose (0.5 mg/kg) of the compound.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Aceto MD, Scates SM, Lowe JA, Martin BR (1996) Δ-9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290–1295

    PubMed  CAS  Google Scholar 

  • Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598–605

    PubMed  CAS  Google Scholar 

  • Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614

    Article  PubMed  CAS  Google Scholar 

  • Arnone M, Maruani J, Chaperon F, Thiebot M-H, Poncelot M, Soubrié P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132:104–106

    Article  PubMed  CAS  Google Scholar 

  • Bays H, Dujovne C (2002) Anti-obesity drug development. Expert Opin Investig Drugs 11:1189–1204

    Article  PubMed  Google Scholar 

  • Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, LeFur G, Oury-Donat F, Soubrie P (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and cultured adipocyte cells. Mol Pharmacol 63:908–914

    Article  PubMed  CAS  Google Scholar 

  • Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, Vera IS, Juan-Pico P, Nadal A, Fuentes E, de Fonseca FR (2006) Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531:282–284

    Article  PubMed  CAS  Google Scholar 

  • Brown JE, Kassouny M, Cross JK (1977) Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta-9-tetrahydrocannabinol. Behav Biol 20:104–110

    Article  PubMed  CAS  Google Scholar 

  • Carai MAM, Colombo G, Gessa GL (2005) Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77:2339–2350

    Article  PubMed  CAS  Google Scholar 

  • Carpino PA (2000) Patent focus on new anti-obesity agents: September 1999–February 2000. Expert Opin Ther Pat 10:819–831

    Article  CAS  Google Scholar 

  • Chambers AP, Sharkley KA, Koopmans HS (2004) Cannabinoid (CB)1 receptor antagonist, AM251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 82:863–869

    Article  PubMed  CAS  Google Scholar 

  • Chambers AP, Koopmans HS, Pittman QJ, Sharkley KA (2006) AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol 147:109–116

    Article  PubMed  CAS  Google Scholar 

  • Chaperon F, Thiébot M-H (1999) Behavioral effects of cannabinoid agents in animals. Crit Revs Neurobiol 13:243–281

    CAS  Google Scholar 

  • Chiesi M, Huppertz C, Hofbauer KG (2001) Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 22:247–254

    Article  PubMed  CAS  Google Scholar 

  • Clapham JC, Arch JRS, Tadayyon M (2001) Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89:81–121

    Article  PubMed  CAS  Google Scholar 

  • Collins P, Williams G (2001) Drug treatment of obesity: from past failures to future successes? Br J Clin Pharmacol 51:13–25

    Article  PubMed  CAS  Google Scholar 

  • Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoids antagonist SR141716A. Life Sci 63:PL113–PL117

    Article  PubMed  CAS  Google Scholar 

  • Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ-9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150–1156

    PubMed  CAS  Google Scholar 

  • Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U (2003a) Endogenous cannabinoid system as a modulator of food intake. Int J Obesity and Relat Metab Disord 27:289–301

    Article  CAS  Google Scholar 

  • Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst ACE, Pasquali R, Lutz B, Stalla GK, Pagotto U (2003b) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423–431

    Article  PubMed  CAS  Google Scholar 

  • Cota D, Tschöp M, Horvath TL, Levine AS (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85–107

    Article  PubMed  CAS  Google Scholar 

  • Coutts AA, Izzo AA (2004) The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4:572–579

    Article  PubMed  CAS  Google Scholar 

  • Darmani NA, Pandya DK (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naïve mice. J Neural Transm 107:931–945

    Article  PubMed  CAS  Google Scholar 

  • Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75:777–787

    Article  PubMed  CAS  Google Scholar 

  • de Fonseca FR, Carrera MRA, Navarro M, Koob GF, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050–2054

    Article  Google Scholar 

  • de Fonseca FR, Del Arco I, Nartin-Calderon JL, Gorriti MA, Navarro M (1998) Role of endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483–501

    Article  Google Scholar 

  • De Vry J, Schrieber R, Eckel G, Jentzsch KR (2004) Behavioral mechaniams underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 483:55–63

    Article  PubMed  CAS  Google Scholar 

  • Despres JP, Golay A, Sjoestroem L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Eng J Med 353:2121–2134

    Article  PubMed  CAS  Google Scholar 

  • Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613

    PubMed  CAS  Google Scholar 

  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949

    Article  PubMed  CAS  Google Scholar 

  • DiMarzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585–589

    Article  CAS  Google Scholar 

  • DiMarzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521–528

    Article  CAS  Google Scholar 

  • Duxon MS, Stretton J, Starr K, Jones DNC, Holland V, Riley G, Jerman J, Brough S, Smart D, Johns A, Chan W, Porter RA, Upton N (2001) Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors with downstream 5-HT2C receptor involvement. Psychopharmacology 153:203–209

    Article  PubMed  CAS  Google Scholar 

  • Freedland CS, Poston JS, Porrino LJ (2000) Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67:265–270

    Article  PubMed  CAS  Google Scholar 

  • Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, de Fonseca FR (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612–9617

    PubMed  CAS  Google Scholar 

  • Greenburg I, Kuehnle J, Mendelson JH, Bernstein JG (1976) Effects of marijuana use on body weight and energy intake in humans. Psychopharmacology 49:79–84

    Google Scholar 

  • Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267

    Article  PubMed  CAS  Google Scholar 

  • Gueudet C, Santucci V, Rinaldi-Carmona M, Soubrié P, Le Fur G (1995) The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. NeuroReport 6:1421–1425

    Article  PubMed  CAS  Google Scholar 

  • Halford JCG, Wanninayake SCD, Blundell JE (1998) Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159–168

    Article  PubMed  CAS  Google Scholar 

  • Halford JCG, Cooper GD, Dovey TM, Ishii Y, Rodgers RJ, Blundell JE (2003) The psychopharmacology of appetite: targets for potential anti-obesity agents. Curr Med Chem 3:283–310

    Article  CAS  Google Scholar 

  • Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98:3662–3665

    Article  PubMed  CAS  Google Scholar 

  • Hao SZ, Avraham Y, Mechoulam R, Berry EM (2000) Low-dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392:147–156

    Article  PubMed  CAS  Google Scholar 

  • Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691–700

    Article  PubMed  CAS  Google Scholar 

  • Higgs S, Williams CM, Kirkham TC (2003) Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after Δ9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 165:370–377

    PubMed  CAS  Google Scholar 

  • Hollister LE (1971) Hunger and appetite after single doses of marijuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 12:45–49

    Google Scholar 

  • Ishii Y, Blundell JE, Halford JCG, Rodgers RJ (2003) Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats. Physiol Behav 79:227–238

    Article  PubMed  CAS  Google Scholar 

  • Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A, Rodgers RJ (2004) Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol Behav 81:129–140

    Article  PubMed  CAS  Google Scholar 

  • Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A, Jeffrey P, Summerfield S, Rodgers RJ (2005) Anorexia and weight loss in male rats 24 h following single dose treatment with orexin-1 receptor antagonist SB-334867. Behav Brain Res 157:331–341

    Article  PubMed  CAS  Google Scholar 

  • Jamshidi N, Taylor DA (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151–1154

    Article  PubMed  CAS  Google Scholar 

  • Janoyan JJ, Crim JL, Darmani NA (2002) Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by Δ-9-THC and other cannabinoids. Pharmacol Biochem Behav 71:155–162

    Article  PubMed  CAS  Google Scholar 

  • Jarbe TUC, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisitied. Pharmacol Biochem Behav 73:911–919

    Article  PubMed  CAS  Google Scholar 

  • Järbe TUC, DiPatrizio NV, Lu D, Makriyannis A (2003) The cannabinoid receptor antagonist SR-141716 does not readily antagonise open-field effects induced by the cannabinoid reeptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809–821

    Article  PubMed  CAS  Google Scholar 

  • Järbe TUC, DiPatrizio NV, Lu D, Makriyannis A (2004) (-)-Adamantyl-Δ8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open field behaviors and antagonism by SR-141716 in rats. Behav Pharmacol 15:517–521

    Article  PubMed  Google Scholar 

  • Järbe TUC, Ross T, DiPatrizion NV, Pandarinathan L, Makriyannis A (2006) Effects of CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 85:243–252

    Article  PubMed  CAS  Google Scholar 

  • Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16:297–313

    Article  PubMed  CAS  Google Scholar 

  • Kirkham TC, Williams CM (2001) Endogenous cannabinoids and appetite. Nutr Res Rev 14:65–86

    Article  CAS  Google Scholar 

  • Kirkham TC, Williams CM, Fezza F, DiMarzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550–557

    Article  PubMed  CAS  Google Scholar 

  • Koch JE, Matthews SM (2001) Delta(9)-tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutr Neurosci 4:179–187

    PubMed  CAS  Google Scholar 

  • Macdonald IA (2000) Obesity: are we any closer to identifying causes and effective tretaments? Trends Pharmacol Sci 21:334–336

    Article  PubMed  CAS  Google Scholar 

  • Maekawa T, Nojima H, Kuraishi Y, Aisaka K (2006) The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol 542:179–783

    Article  PubMed  CAS  Google Scholar 

  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA 561. Nature 346:561–564

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishwari K, Makriyannis A, Salamone JD (2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14:583–588

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin PJ, Quan L, Wood JT, Wisniecki A, Winston KM, Swezey LA, Ishiwari K, Betz AJ, Pandarinathan L, Xu W, Makriyannis A, Salamone JD (2006) Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 83:396–402

    Article  PubMed  CAS  Google Scholar 

  • Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that nids to cannabinoid receptors. Biochem Pharmacol 50:83–90

    Article  PubMed  CAS  Google Scholar 

  • Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65

    Article  PubMed  CAS  Google Scholar 

  • Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MRA, de Fonseca FR (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport 8:491–496

    Article  PubMed  CAS  Google Scholar 

  • NIH Obesity Research Task Force (2004) http://www.obesityresearch.nih.gov

  • Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298–1305

    Article  PubMed  CAS  Google Scholar 

  • Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, Abellan G, Rodriguez-Franco MI, Serrano A, Macias M, Gomez R, Navarro M, Goya P, de Fonseca FR (2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-trazole-LH21. Neuropharmacology 51:358–366

    Article  PubMed  CAS  Google Scholar 

  • Pertwee RG (2005) Inverse agonism and neural antagonism at cannabinoid CB1 receptors. Life Sci 76:1307–1324

    Article  PubMed  CAS  Google Scholar 

  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomised controlled trial. J Am Med Assoc 295:761–775

    Article  CAS  Google Scholar 

  • Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45–60

    Article  PubMed  CAS  Google Scholar 

  • Rennie KL, Jebb SA (2005) Prevalence of obesity in Great Britain. Obes Rev 6:11–12

    Article  PubMed  CAS  Google Scholar 

  • Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244

    Article  PubMed  CAS  Google Scholar 

  • Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere J-C, Le Fur G (1995) Biochemical and pharmacological characteristics of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941–1947

    Article  PubMed  CAS  Google Scholar 

  • Rodgers RJ, Halford JCG, Nunes de Souza N, Canto de Souza AL, Piper DC, Arch JRS, Upton N, Porter RA, Johns A, Blundell JE (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13:1444–1452

    Article  PubMed  CAS  Google Scholar 

  • Rodgers RJ, Ishii Y, Halford JCG, Blundell JE (2002) Orexins and appetite regulation. Neuropeptides 36:303–325

    Article  PubMed  CAS  Google Scholar 

  • Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giagnoni G, Parolaro D (1998) Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 285:813–819

    PubMed  CAS  Google Scholar 

  • Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102:283–288

    Article  PubMed  CAS  Google Scholar 

  • Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14:573–582

    Article  PubMed  CAS  Google Scholar 

  • Ständer S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibres and adnexal structures in the human skin. J Dermatol Sci 38:177–188

    Article  PubMed  CAS  Google Scholar 

  • Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG (2006) The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84:353–359

    Article  PubMed  CAS  Google Scholar 

  • Tucci SA, Halford JCG, Harrold JA, Kirkham TC (2006) Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Current Med Chem 13:2669–2680

    Article  CAS  Google Scholar 

  • Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397

    Article  PubMed  CAS  Google Scholar 

  • Verty AN, McGregor IS, Mallet PE (2004) Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354:217–220

    Article  PubMed  CAS  Google Scholar 

  • Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003) Preferential effects of the cannabinoids CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167:103–111

    PubMed  CAS  Google Scholar 

  • Webster LJ, Kennett GA, Vickers SP (2003) Effect of the CB1 receptor antagonist SR 141716 on food intake, bodyweight and the behavioural satiety sequence in obese (fa/fa) Zucker rats. Br J Pharmacol 138:106P

    Google Scholar 

  • Weiss SM (1995) Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny owl. PhD thesis, School of Psychology, University of Leeds

  • Werner NA, Koch JE (2003) Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 967:2290–2292

    Article  CAS  Google Scholar 

  • Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293–300

    Article  PubMed  CAS  Google Scholar 

  • Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid receptors. Psychopharmacology 143:315–317

    Article  PubMed  CAS  Google Scholar 

  • Williams CM, Kirkham TC (2002a) Observational analysis of feeding induced by delta(9)-THC and anandamide. Physiol Behav 76:241–250

    Article  PubMed  CAS  Google Scholar 

  • Williams CM, Kirkham TC (2002b) Reversal of Ä9 -THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71:341–348

    Article  Google Scholar 

  • Williams CM, Rogers PJ, Kirkham TC (1998) Hyperphagia in pre-fed rats following oral Δ-9-THC. Physiol Behav 65:343–346

    Article  PubMed  CAS  Google Scholar 

  • Wilson DM, Varvel S, Harloe JP, Martin BR, Lichtman AH (2006) SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav 85:105–113

    Article  PubMed  CAS  Google Scholar 

  • World Health Organisation (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series No. 84, ISBN 92 4 120894 5

Download references

Acknowledgements

The authors are most grateful to Sanofi-Aventis for the kind gift of rimonabant.

Author information

Authors and Affiliations

  1. Behavioural Neuroscience Laboratory, Institute of Psychological Sciences, University of Leeds, Leeds, LS2 9JT, UK

    A. J. Tallett, J. E. Blundell & R. J. Rodgers

Authors
  1. A. J. Tallett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. E. Blundell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. J. Rodgers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. J. Rodgers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tallett, A.J., Blundell, J.E. & Rodgers, R.J. Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195, 27–39 (2007). https://doi.org/10.1007/s00213-007-0880-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-007-0880-2

Keywords

Search

Navigation